tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

OCUP Stock Latest News

Ocuphire Pharma announces presentations on development of APX3330
The FlyOcuphire Pharma announces presentations on development of APX3330
29d ago
OCUP
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
PremiumPress Releases
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
29d ago
OCUP
Ocuphire Pharma price target lowered to $18 from $22 at Canaccord
PremiumThe Fly
Ocuphire Pharma price target lowered to $18 from $22 at Canaccord
2M ago
OCUP
Ocuphire Pharma Gambles on Cash-Pay Strategy for RYZUMVI: Is It a Path to Profit or a Financial Pitfall?
PremiumCompany Announcements
Ocuphire Pharma Gambles on Cash-Pay Strategy for RYZUMVI: Is It a Path to Profit or a Financial Pitfall?
2M ago
OCUP
Ocuphire Pharma Shares Updates in Upcoming Investor Meetings
PremiumCompany Announcements
Ocuphire Pharma Shares Updates in Upcoming Investor Meetings
2M ago
8K
OCUP
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
PremiumPress ReleasesOcuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
2M ago
OCUP
Ocuphire Pharma reports Q1 EPS (29c), consensus (13c)
PremiumThe Fly
Ocuphire Pharma reports Q1 EPS (29c), consensus (13c)
2M ago
OCUP
Ocuphire Pharma announces presentation on APX3330 at ARVO 2024
PremiumThe Fly
Ocuphire Pharma announces presentation on APX3330 at ARVO 2024
2M ago
OCUP
Ocuphire Pharma to Present at the Aegis Virtual Conference
PremiumPress Releases
Ocuphire Pharma to Present at the Aegis Virtual Conference
2M ago
OCUP
OCUP Earnings this Week: How Will it Perform?
PremiumPre-Earnings
OCUP Earnings this Week: How Will it Perform?
2M ago
OCUP
Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options
PremiumCompany Announcements
Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options
3M ago
8K
OCUP
Ocuphire Pharma announces enrollment of first patient in LYNX-2 Phase 3 study
PremiumThe Fly
Ocuphire Pharma announces enrollment of first patient in LYNX-2 Phase 3 study
3M ago
OCUP
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
PremiumPress ReleasesFirst Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
3M ago
OCUP
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
PremiumPress Releases
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
3M ago
OCUP
Ocuphire Pharma announces U.S. commercial launch of RYZUMVI
PremiumThe Fly
Ocuphire Pharma announces U.S. commercial launch of RYZUMVI
3M ago
OCUP
VTRS
Ocuphire Pharma Engages Investors with Presentation Update
PremiumCompany Announcements
Ocuphire Pharma Engages Investors with Presentation Update
3M ago
8K
OCUP
Ocuphire Pharma price target lowered to $20 from $24 at Alliance Global
PremiumThe Fly
Ocuphire Pharma price target lowered to $20 from $24 at Alliance Global
4M ago
OCUP
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
PremiumPress Releases
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
4M ago
OCUP
Ocuphire Pharma expects cash to fund operations into mid-2025
PremiumThe Fly
Ocuphire Pharma expects cash to fund operations into mid-2025
4M ago
OCUP
Ocuphire Pharma reports Q4 EPS (21c), consensus (5c)
PremiumThe FlyOcuphire Pharma reports Q4 EPS (21c), consensus (5c)
4M ago
OCUP
OCUP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
OCUP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
OCUP
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
PremiumPress Releases
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
4M ago
OCUP

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >